|
|
|
|
The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis [La mutation JAK2 dans les syndromes myéloprolifératifs BCR-ABL négatifs: facteur prédictif de thrombose]
|
|
|
|
|
|
|
|
نویسنده
|
|
|
منبع
|
tunisie médicale - 2015 - دوره : 93 - شماره : 7 - صفحه:474 -477
|
|
چکیده
|
Background: bcr-abl negative myeloproliferative neoplasms (mpn) include polycythemia vera (pv),essential thrombocythemia (et) and primitive myelofibrosis (pmf). the jak2 v617f mutation has been introduced since 2008 as a major diagnostic criterion on the one hand and on the other hand,it would be linked to increased risk of thrombotic complications.aim: this study aimed to evaluate the association of jak2 mutation and thrombotic events in mpn.methods: a retrospective study concerning 45 bcr-abl negative mpn patients (mean age=53 old years,sex ratio=0.8) was conducted.results: they were classified as pv (22 patients),et (17 patients),pmf (3 patients) and atypical mpn (3 patients). the jak2 mutation was found in 64.4% of patients: 72.7% of pv patients,47% of et patients and 66.7% of pmf patients. thrombotic events were recorded in 11 patients (24.4%). cerebral arteries and portal vein were the most frequent localizations. the jak2 mutation was an independent risk factor of thrombotic events.conclusion: consequently,it seems that screening for jak2 mutation in bcr-abl negative mpn could play a role in identifying patients at high risk of vascular complications.
|
|
|
|
|
آدرس
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|